Skip to main content
Journal cover image

Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f): long-term treatment in azoospermic men with hypogonadotropic hypogonadism.

Publication ,  Journal Article
Matsumoto, AM; Snyder, PJ; Bhasin, S; Martin, K; Weber, T; Winters, S; Spratt, D; Brentzel, J; O'Dea, L
Published in: Fertil Steril
September 2009

OBJECTIVE: To demonstrate the efficacy and safety of follitropin alfa administered with hCG on spermatogenesis in adult male hypogonadotropic hypogonadism (HH) patients. DESIGN: Phase III, multicenter, open-label, noncomparative. SETTING: Seven US medical centers. PATIENT(S): A total of 36 adult males with severe HH. INTERVENTION(S): A total of 1,000 U hCG on alternate days for 3 to 6 months, with dose adjustments after 2 months, if necessary, to normalize T levels, followed by follitropin alfa 150 U and hCG on the same alternate days for 18 months, with dose adjustments as necessary. MAIN OUTCOME MEASURE(S): Proportion of patients with sperm density > or =1.5 x 10(6)/mL. Pubertal advancement and long-term safety and tolerability were also evaluated. RESULT(S): In total, 22 of 29 patients (75.9%) who received > or =1 dose of follitropin alfa and 20 of 25 patients (80%) who completed 18 months of hCG + follitropin alfa treatments achieved a sperm concentration > or =1.5 x 10(6)/mL. A sperm concentration >20 x 10(6)/mL was achieved by 8 of 29 men (27.5%). Median sperm concentration at 18 months was 5.2 x 10(6)/mL. Pubertal development continued during the study, and testis volumes increased. Five clinical pregnancies were achieved. Acne (52% of patients) was the most common side effect, and gynecomastia was reported in 10% of patients. CONCLUSION(S): Long-term treatment of azoospermic HH men using follitropin alfa and hCG is effective for stimulating spermatogenesis and is well-tolerated.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Fertil Steril

DOI

EISSN

1556-5653

Publication Date

September 2009

Volume

92

Issue

3

Start / End Page

979 / 990

Location

United States

Related Subject Headings

  • Young Adult
  • United States
  • Treatment Outcome
  • Testosterone
  • Testis
  • Spermatozoa
  • Spermatogenesis
  • Sperm Motility
  • Organ Size
  • Obstetrics & Reproductive Medicine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Matsumoto, A. M., Snyder, P. J., Bhasin, S., Martin, K., Weber, T., Winters, S., … O’Dea, L. (2009). Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f): long-term treatment in azoospermic men with hypogonadotropic hypogonadism. Fertil Steril, 92(3), 979–990. https://doi.org/10.1016/j.fertnstert.2008.07.1742
Matsumoto, Alvin M., Peter J. Snyder, Shalender Bhasin, Kathryn Martin, Thomas Weber, Stephen Winters, Daniel Spratt, Jim Brentzel, and Louis O’Dea. “Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f): long-term treatment in azoospermic men with hypogonadotropic hypogonadism.Fertil Steril 92, no. 3 (September 2009): 979–90. https://doi.org/10.1016/j.fertnstert.2008.07.1742.
Matsumoto, Alvin M., et al. “Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f): long-term treatment in azoospermic men with hypogonadotropic hypogonadism.Fertil Steril, vol. 92, no. 3, Sept. 2009, pp. 979–90. Pubmed, doi:10.1016/j.fertnstert.2008.07.1742.
Matsumoto AM, Snyder PJ, Bhasin S, Martin K, Weber T, Winters S, Spratt D, Brentzel J, O’Dea L. Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f): long-term treatment in azoospermic men with hypogonadotropic hypogonadism. Fertil Steril. 2009 Sep;92(3):979–990.
Journal cover image

Published In

Fertil Steril

DOI

EISSN

1556-5653

Publication Date

September 2009

Volume

92

Issue

3

Start / End Page

979 / 990

Location

United States

Related Subject Headings

  • Young Adult
  • United States
  • Treatment Outcome
  • Testosterone
  • Testis
  • Spermatozoa
  • Spermatogenesis
  • Sperm Motility
  • Organ Size
  • Obstetrics & Reproductive Medicine